SEARCH

SEARCH BY CITATION

References

  • Amadori, S., Suciu, S., Stasi, R., Willemze, R., Mandelli, F., Selleslag, D., Denzlinger, C., Muus, P., Stauder, R., Berneman, Z., Pruijt, J., Nobile, F., Cassibba, V., Marie, J.P., Beeldens, F., Baila, L., Vignetti, M. & De Witte, T. (2005) Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell’Adulto Leukemia Groups. Leukemia, 19, 17681773.
  • Appelbaum, F.R., Gundacker, H., Head, D.R., Slovak, M.L., Willman, C.L., Godwin, J.E., Anderson, J.E. & Petersdorf, S.H. (2006) Age and acute myeloid leukemia. Blood, 107, 34813485.
  • Burnett, A.K., Milligan, D., Prentice, A.G., Goldstone, A.H., McMullin, M.F., Hills, R.K. & Wheatley, K. (2007) A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer, 109, 11141124.
  • Van Der Velden, V.H., Te Marvelde, J.G., Hoogeveen, P.G., Bernstein, I.D., Houtsmuller, A.B., Berger, M.S. & Van Dongen, J.J. (2001) Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood, 97, 31973204.
  • Estey, E.H. (2007) Advances in the management of AML in the elderly. Clinical Advances in Hematology and Oncology, 5, 185187.
  • Estey, E.H. (2009) Treatment of acute myeloid leukemia. Haematologica, 94, 1016.
  • Freemantle, N. & Calvert, M. (2007) Composite and surrogate outcomes in randomised controlled trials. British Medical Journal, 334, 756757.
  • Freemantle, N., Calvert, M., Wood, J., Eastaugh, J. & Griffin, C. (2003) Composite outcomes in randomized trials: greater precision but with greater uncertainty? Journal of the American Medical Association, 289, 25542559.
  • Larson, R.A., Sievers, E.L., Stadtmauer, E.A., Lowenberg, B., Estey, E.H., Dombret, H., Theobald, M., Voliotis, D., Bennett, J.M., Richie, M., Leopold, L.H., Berger, M.S., Sherman, M.L., Loken, M.R., Van Dongen, J.J., Bernstein, I.D. & Appelbaum, F.R. (2005) Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer, 104, 14421452.
  • Latagliata, R., Bongarzoni, V., Carmosino, I., Mengarelli, A., Breccia, M., Borza, P.A., D’Andrea, M., D’Elia, G.M., Mecarocci, S., Morano, S.G., Petti, M.C., Mandelli, F. & Alimena, G. (2006) Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon. Annals of Oncology, 17, 281285.
  • Menzin, J., Lang, K., Earle, C.C., Kerney, D. & Mallick, R. (2002) The outcomes and costs of acute myeloid leukemia among the elderly. Archives of Internal Medicine, 162, 15971603.
  • Scheinberg, D.A., Lovett, D., Divgi, C.R., Graham, M.C., Berman, E., Pentlow, K., Feirt, N., Finn, R.D., Clarkson, B.D., Gee, T.S., Larson, S.M., Oettgen, H.F. & Old, L.J. (1991) A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. Journal of Clinical Oncology, 9, 478490.
  • Sievers, E.L., Appelbaum, F.R., Spielberger, R.T., Forman, S.J., Flowers, D., Smith, F.O., Shannon-Dorcy, K., Berger, M.S. & Bernstein, I.D. (1999) Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood, 93, 36783684.
  • Sievers, E.L., Larson, R.A., Stadtmauer, E.A., Estey, E., Lowenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J.M., Sherman, M.L., Berger, M.S., Eten, C.B., Loken, M.R., Van Dongen, J.J., Bernstein, I.D. & Appelbaum, F.R. (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. Journal of Clinical Oncology, 19, 32443254.
  • Stasi, R., Evangelista, M.L., Buccisano, F., Venditti, A. & Amadori, S. (2008) Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treatment Reviews, 34, 4960.
  • Taksin, A.L., Legrand, O., Raffoux, E., De Revel, T., Thomas, X., Contentin, N., Bouabdallah, R., Pautas, C., Turlure, P., Reman, O., Gardin, C., Varet, B., De Botton, S., Pousset, F., Farhat, H., Chevret, S., Dombret, H. & Castaigne, S. (2007) High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia, 21, 6671.
  • Vardiman, J.W., Harris, N.L. & Brunning, R.D. (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood, 100, 22922302.